These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 24346637)

  • 21. A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers.
    Mora-Peris B; Else L; Goldmeier D; Mears A; Weston R; Cooke G; Khoo S; Back D; Winston A
    J Antimicrob Chemother; 2015; 70(6):1812-5. PubMed ID: 25693997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
    Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
    J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
    Hézode C; Fontaine H; Dorival C; Larrey D; Zoulim F; Canva V; de Ledinghen V; Poynard T; Samuel D; Bourlière M; Zarski JP; Raabe JJ; Alric L; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Métivier S; Tran A; Serfaty L; Abergel A; Causse X; Di Martino V; Guyader D; Lucidarme D; Grando-Lemaire V; Hillon P; Feray C; Dao T; Cacoub P; Rosa I; Attali P; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    J Hepatol; 2013 Sep; 59(3):434-41. PubMed ID: 23669289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HCV viral load at baseline and at week 4 of telaprevir/boceprevir based triple therapies are associated with virological outcome in HIV/hepatitis C co-infected patients.
    Salmon D; Bani-Sadr F; Gilbert C; Rosenthal E; Valantin MA; Simon A; Neau D; Morlat P; Loko MA; Wittkop L; Dabis F;
    J Clin Virol; 2015 Dec; 73():32-35. PubMed ID: 26528903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.
    Cammà C; Petta S; Enea M; Bruno R; Bronte F; Capursi V; Cicchetti A; Colombo GL; Di Marco V; Gasbarrini A; Craxì A;
    Hepatology; 2012 Sep; 56(3):850-60. PubMed ID: 22454336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
    Gutierrez-Valencia A; Ruiz-Valderas R; Torres-Cornejo A; Viciana P; Espinosa N; Castillo-Ferrando JR; Lopez-Cortes LF
    Clin Infect Dis; 2014 Jan; 58(2):268-73. PubMed ID: 24145880
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
    Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
    J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal impairment in patients with chronic hepatitis C treated with first generation protease inhibitors.
    Kozielewicz D; Dybowska D; Karwowska K; Wietlicka-Piszcz M
    Expert Opin Drug Saf; 2015; 14(12):1815-25. PubMed ID: 26513231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.
    Massud I; Aung W; Martin A; Bachman S; Mitchell J; Aubert R; Solomon Tsegaye T; Kersh E; Pau CP; Heneine W; García-Lerma JG
    J Virol; 2013 Aug; 87(16):8952-61. PubMed ID: 23740994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
    Abel S; van der Ryst E; Rosario MC; Ridgway CE; Medhurst CG; Taylor-Worth RJ; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):5-18. PubMed ID: 18333861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poor Sustained Virological Response in a Multicenter Real-Life Cohort of Chronic Hepatitis C Patients Treated with Pegylated Interferon and Ribavirin plus Telaprevir or Boceprevir.
    Vo KP; Vutien P; Akiyama MJ; Vu VD; Ha NB; Piotrowski JI; Wantuck J; Roytman MM; Tsai N; Cheung R; Li J; Nguyen MH
    Dig Dis Sci; 2015 Apr; 60(4):1045-51. PubMed ID: 25821099
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.
    Mora-Peris B; Croucher A; Else LJ; Vera JH; Khoo S; Scullard G; Back D; Winston A
    J Antimicrob Chemother; 2013 Jun; 68(6):1348-53. PubMed ID: 23364475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
    Cure S; Diels J; Gavart S; Bianic F; Jones E
    Curr Med Res Opin; 2012 Nov; 28(11):1841-56. PubMed ID: 23016967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis.
    Salmerón J; Vinaixa C; Berenguer R; Pascasio JM; Sánchez Ruano JJ; Serra MÁ; Gila A; Diago M; Romero-Gómez M; Navarro JM; Testillano M; Fernández C; Espinosa D; Carmona I; Pons JA; Jorquera F; Rodriguez FJ; Pérez R; Montero JL; Granados R; Fernández M; Martín AB; Muñoz de Rueda P; Quiles R;
    World J Gastroenterol; 2015 Aug; 21(30):9163-74. PubMed ID: 26290644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The maraviroc expanded access program - safety and efficacy data from an open-label study.
    Lazzarin A; Reynes J; Molina JM; Valluri S; Mukwaya G; Heera J; Craig C; van der Ryst E; Sierra-Madero JG
    HIV Clin Trials; 2015; 16(1):10-21. PubMed ID: 25777185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice].
    Giménez-Manzorro Á; García-González X; Rodríguez-González CG; Ochoa-Palominos A; Sanjurjo-Sáez M; Clemente-Ricote G
    Gastroenterol Hepatol; 2015 Dec; 38(10):575-82. PubMed ID: 26321320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short Communication: Maraviroc Once-Daily: Experience in Routine Clinical Practice.
    Saumoy M; Llibre JM; Terrón A; Knobel H; Arribas JR; Domingo P; Arroyo-Manzano D; Rivero A; Moreno S; Podzamczer D
    AIDS Res Hum Retroviruses; 2017 Jan; 33(1):29-32. PubMed ID: 27250802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.